Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
In addition to the above: * To evaluate the overall survival after three years. * To determine the rate of global responses and complete remissions, uncertain and partial. * To determine the duration of the complete response after the treatment termination. * To carry out an exploratory follow up of the event free survival and the overall survival at 5 years. * To evaluate the treatment toxicity according CTC criteria (version 3.0) of the National Cancer Institute (NCI). * To asses the role of PET in the disease stage and response evaluation compared to CAT. * To identify the predictable response factors after 6 cycles of treatment with R-MegaCHOP administrated every 21 days; or 3 cycles of R-MegaCHOP, followed by IFE+TAPH in patients with DLBCL of severe prognosis. * To evaluate the therapeutic fulfillment of the R-MegaCHOP and R+IFE cycles of treatment and/or R-IFE in reference with delays with the cycles administration and reductions of the chemotherapy dose (planned dose administrated in the planned term).
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
